Online inquiry

IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10642MR)

This product GTTS-WQ10642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ402MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ10442MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ5698MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ12324MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ12365MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ3774MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10766MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ6625MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW